From: “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis
Variable | Patients (n = 13) | |
---|---|---|
HCV Genotype 1 | 13 (100%) | |
Fibrosis stage 0-1 | 1 (8%) | |
Fibrosis stage 2 | 3 (23%) | |
Fibrosis stage 3 | 3 (23%) | |
Fibrosis stage 4 | 6 (46%) | |
Gender | Male | 8 (62%) |
Female | 5 (38%) | |
Mean age in years (range) | 49 (36–63) | |
Transmission | IDU1 | 6 (46%) |
Blood products | 2 (15%) | |
Unsafe sex | 1 (8%) | |
Unsafe tattooing | 1 (8%) | |
Unknown | 3 (23%) | |
Opioid substitution | 3 (23%) | |
Multimorbidity2 | 4 (30%) | |
First diagnosed mean years (range) | 12.5 (1.5 - 28) | |
Treatment experience | Naive | 5 (38%) |
Dual therapy 1× | 7 (54%) | |
Dual therapy 2× | 1 (8%) | |
Protease inhibitor | Telaprevir | 9 (70%) |
Boceprevir | 4 (30%) | |
Status proteaseinhibitor therapy | Ongoing | 5 (38%) |
Completed | 5 (38%) | |
Discontinued3 | 3 (23%) | |
Residence situation | With Partner/Family | 8 (62%) |
alone | 3 (23%) | |
Institution4 | 2 (15%) | |
Occupation before triple therapy | 10 (80%) | |
Job related working ability during triple therapy | 0-25% | 5 (50%) |
26-50% | 1 (10%) | |
51-75% | 1 (10%) | |
76-100% | 3 (30%) |